THE SCIENCE

TYNA-1 is a powerful new treatment to help people free themselves from smoking addiction and improve their overall health and quality of life.

TYNA-1 is a dopamine receptor type 3 agonist, which replaces an individual’s ability to experience rewards after quitting smoking. TYNA-1 combines a unique and powerful combination of the best that cannabinoids and MAO inhibitors have to offer to permit people who smoke to rid themselves of the cravings and rewards of smoking while preventing the withdrawal symptoms that cause high rates of relapse.

TYNA-1 is a patented, new chemical entity that is being developed to treat nicotine dependence and obesity. TYNA-1 is a synthetic cannabinoid analog of THCV.

Unlike THC, which is intoxicating because it activates CB1 receptors in the brain, TYNA-1 is a CB1 blocker and a CB2 activator—both of which help in the treatment of addiction.

In addition to nicotine, tobacco smoke contains components that block Monoamine Oxidase (MAO), which increases the brain’s dopamine levels and stimulates the brain’s reward center. MAO comes in two forms: MAO A, which when blocked by tobacco increases the reward signals derived from smoking; and MAO B, which when no longer blocked by tobacco drives most of the withdrawal symptoms experienced during smoking cessation. Withdrawal Syndrome is responsible for the ineffectiveness and high rate of relapse associated with currently available treatments for nicotine dependence.

We believe that the pharmacokinetics data of TYNA-1 may support cessation after the first dose.

TYNA-1’s profile shows its inhibition of MAO B relative to MAO A is 80 fold greater than that of nicotine, demonstrating TYNA’s potent ability to block the reward signals from smoking while simultaneously preventing the withdrawal symptoms from smoking cessation.

Source: Eurofins Panlabs Discovery Services Taiwan, Ltd., and Johns Hopkins School of Medicine.

An Unmet Need

The global tobacco market size was valued at USD 849.9 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 2.4% from 2022 to 2030. Cigarette smoking cost the United States more than $600 billion in 2018, including:

Healthcare spending related to smoking

Lost productivity due to illnesses and health conditions from smoking

Lost productivity due to premature death from smoking

Lost productivity due to premature death from secondhand smoke exposure

https://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/smoking-cessation-fast-facts/index.html

https://www.grandviewresearch.com/industry-analysis/tobacco-market

Most Adult Smokers Want to Quit!

Smokers who said they want to quit (2015) (22.7 million)

Adult smokers who try and succeed in quitting each year

Adult smokers who successfully quit in 2018 (2.9 million)

https://www.cdc.gov/tobacco/data_statistics/fact_sheets/economics/econ_facts/index.htm